Targeted treatment strategies for menstrual migraine

Journal of Family Practice

Volumn , Issue SUPPL., 2007, Pages 13-22

  Martin, Vincent ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTORPHANOL; CAFFEINE; DICHLORALPHENAZONE; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; ESTRADIOL; FROVATRIPTAN; ISOMETHEPTENE; MAGNESIUM; MEFENAMIC ACID; METHYLERGOMETRINE MALEATE; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN; CYTOKINE; ERGOTAMINE DERIVATIVE; ESTROGEN; PLAB PROTEIN; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; LOADING DRUG DOSE; MENSTRUAL MIGRAINE; NAUSEA; ONSET AGE; PERCUTANEOUS DRUG ADMINISTRATION; PREVALENCE; QUESTIONNAIRE; RELAXATION TRAINING; REVIEW; SCORING SYSTEM; SYMPTOM; ACUTE DISEASE; ADULT; MENSTRUATION DISORDER; METABOLISM; MIGRAINE;

ACUTE DISEASE; ADULT; CYTOKINES; ERGOTAMINES; ESTROGENS; FEMALE; HUMANS; MAGNESIUM; MENSTRUATION DISTURBANCES; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 33847094971     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Lipton RB, Stewart WE, Diamonds, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Stewart WP, Linet MS, Celentano DD, Van Natta M, Ziegler D. Age- and sex-specific incidence rates of migraine with and without visual aura. Am J Epidemiol. 1991;134:1111-1120.
3. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis-part 2. Headache. 2006;46:365-386.
4. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia. 2003;23:197-205.
5. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385-389.
6. Neri I, Granella F, Nappi R, Manzoni GC, Facchinetti F, Genazzani AR. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993;17:31-37.
7. Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55:1517-1523.
8. Johannes CB, Linet MS, Stewart WF, Celentano DD, Lipton RB, Szklo M. Relationship of headache to phase of the menstrual cycle among young women: a daily diary study. Neurology. 1995;45:1076-1082.
9. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
10. Headache Classification Subcommittee, International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
11. Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
12. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep. 2004;8:229-237.
13. MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia. 1990;10:305-310.
14. Cupini LM, Matteis M, Troisi E, Calabresi P, Bernardi G, Silvestrini M. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995;15:140-144.
15. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache. 2003;43:27-35.
16. Koseoglu E, Nacar M, Talasliogiu A, Cetinkaya F. Epidemiological and clinical characteristics of migraine and tension type headache in 1146 females in Kayseri, Turkey. Cephalalgia. 2003;23:381-388.
17. Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA. 2006;295:1824-1830.
18. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and non menstrual attacks in women with menstrually related migraine [abstract]. Cephalalgia. 2001;21:263-264.
19. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190-1201.
20. Somerville BW. The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology. 1972;22:355-365.
21. Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology. 1975;25:239-244.
22. Somerville BW. The role of progesterone in menstrual migraine. Neurology. 1971;21:853-859.
23. Stein G, Morton J, Marsh A, et al. Headaches after childbirth. Acta Neurol Scand. 1984;69:74-79.
24. Whitty CW, Hockaday JM, Whitty MM. The effect of oral contraceptives on migraine. Lancet. 1966;1:856-859.
25. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the depo-estradiol challenge test. Headache. 1996;36:367-371.
26. Martin V, Behbehani M. Changes in the response characteristics of trigeminal nucleus caudalis (TNC) neurons after dural activation during different stages of the rat estrous cycle. Presented at: Migraine Trust; 2006; London, United Kingdom.
27. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis-part I. Headache. 2006;46:3-23.
28. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5:24-27.
29. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci (Lond). 1995;89:633-636.
30. Benedetto C, Allais G, Ciochetto D, De Lorenzo C. Pathophysiological aspects of menstrual migraine. Cephalalgia. 1997;17(suppl 20):32-34.
31. Martin VT. Simplifying the diagnosis of migraine headache. Adv Stud Med. 2004;4:200-207.
32. Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine(TM) validation study. Neurology. 2003;61:375-382.
33. Martin VT, Penzien DB, Houle TT, Andrew ME, Lofland KR. The predictive value of abbreviated migraine diagnostic criteria. Headache. 2005;45:1102-1112.
34. Stewart WF, Lipton RB, Kotodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000;88:41-52.
35. Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin. 2001;17:298-309.
36. US Headache Consortium. American Academy of Neurology Web site. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acure attacks. Available at: www.aan.com/ professionals/practice/pdfs/g10087.pdf. Accessed October 23, 2006.
37. Martin VT, Behbehani MM. Toward a rational understanding of migraine trigger factors. Med Clin North Am. 2001;85:911-941.
38. Lay CL, Broner SW. Special considerations in the treatment of migraine in women. Semin Neurol. 2006;26:217-222.
39. Snow V, Weiss K, Wall EM, Mottur-Pilson C. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840-849.
40. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.
41. Klapper JA, Rosjo O, Charlesworth B, Jergensen AP, Soisson T. Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain-free response rates in patients with significant migraine-related disability [abstract]. Neurology. 2002;58:A416.
42. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
43. Jelinski SE, Becker WJ, Christie SN, Ahrnad FE, Pryse-Phillips W, Simpson SD. Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci. 2006;33:73-79.
44. Carpay J, Schoenen J, Ahrnad F, Kinrade F, Boswell D. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004;26:214-223.
45. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther. 2005;27:1785-1794.
46. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 1.0 mg administered early in a migraine attack. Headache. 2006;46:914-924.
47. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia. 2005;25:735-742.
48. Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache. 2002;42:917-923.
49. Silberstein SD, Massiou H, Le Jeunne C, Johnson-Pratt L, McCarroll KA, Lines CR. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol. 2000;96:237-242.
50. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol. 1993;82:769-772.
51. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004;44:120-130.
52. Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005;12:774-781.
53. Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache, 2002;42(suppl 2):S84-S92.
54. Nett R, Landy S, Shackelford S, Richardson MS, Ames M, Lener M. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol. 2003;102:835-842.
55. Allais G, Acuto G, Cabarrocas X, Esbri R, Benedetto C, Bussone G. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci. 2006;27(suppl 2):S193-S197.
56. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44:414-425.
57. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache. 1995;35:65-69.
58. Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the nonprescription combination of acetaminophen, aspirin, and caffeine: results from three randomized, placebo-controlled studies. Clin Ther. 1999;21:475-491.
59. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998;51:307-309.
60. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
61. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41:248-256.
62. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache. 1990;30:705-709.
63. Szekely B, Merryman S, Croft H, et al. Prophylactic effects of naproxen sodium on perimenstrual headache: a double-blind, placebo-controlled study. Cephalalgia. 1989;9(suppl 10):452-453.
64. Gallagher RM. Menstrual migraine and intermittent ergonovine therapy. Headache. 1989;29:366-367.
65. Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31:298-301.
66. de Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. Br Med J (Clin Res Ed). 1986;293:1540.
67. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecol Endocrinol. 1988;2:113-120.
68. Pfaffenrath V. Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine [abstract]. Cephalalgia. 1993;13(suppl 13):244.
69. Smits MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ. Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache. 1994;34:103-106.
70. Bousser MG. Estrogens, migraine, and stroke. Stroke. 2004;35(11 suppl 1):2652-2656.
71. Calhoun AH. A novel specific prophylaxis for menstrual-associated migraine. South Med J. 2004;97:819-822.
72. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434.
73. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:772-780.
74. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295:1647-1657.
75. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med. 2006;166:357-365.
76. Sargent J, Solbach P, Damasio H, et al. A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache. 1985;25:320-324.
77. Herzog AG. Continuous bromocriptine therapy in menstrual migraine. Neurology. 1997;48:101-102.
78. Cachrimanidou AC, Hellberg D, Nilsson S, Waldenstrom U, Olsson SE, Sikstrom B. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993;48:205-216.